|
Euroscreen SA pursues a dual business model strategy of combining:
• its internal programs on high value targets (Euroscreen DRUG DISCOVERY) discovering and developing innovative small molecules as preclinical candidates targeting proprietary G Protein-Coupled Receptors (GPCR) for unmet medical needs,
• with its fully dedicated Business Unit (Euroscreen FAST) by providing GPCR customized screening and other services for biotech and pharma companies around the world.
Euroscreen has also developed a broad target portfolio for licensing intellectual property rights to pharmaceutical companies for the development of therapeutics that act through these targets, including CCR5, Chemerin receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2. Read more...
|
|
|
